Visually Estimated MRI Targeted Prostate Biopsy Could Improve the Detection of Significant Prostate Cancer in Patients with a PSA Level <10 ng/mL
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To compare prostate cancer detection rates between 12 cores transrectal ultrasound-guided prostate biopsy (TRUS-Bx) and visually estimated multiparametric magnetic resonance imaging (mp-MRI)-targeted prostate biopsy (MRI-visual-Bx) for patientswith prostate specific antigen (PSA) level less than 10 ng/mL. Materials and Methods: In total, 76 patients with PSA levels below 10 ng/mL underwent 3.0 Tesla mp-MRI and TRUS-Bx prospectivelyin 2014. In patients with abnormal lesions on mp-MRI, we performed additional MRI-visual-Bx. We compared pathologic results,including the rate of clinically significant prostate cancer cores (cancer length greater than 5 mm and/or any Gleason grade greater than 3 in the biopsy core). Results: The mean PSA was 6.43 ng/mL. In total, 48 of 76 (63.2%) patients had abnormal lesions on mp-MRI, and 116 targeted biopsycores, an average of 2.42 per patient, were taken. The overall detection rates of prostate cancer using TRUS-Bx and MRI-visual-Bx were 26/76 (34.2%) and 23/48 (47.9%), respectively. In comparing the pathologic results of TRUS-Bx and MRI-visual-Bx cores, the positive rates were 8.4% (77 of 912 cores) and 46.6% (54 of 116 cores), respectively (p<0.001). Mean cancer core lengths and mean cancer core percentages were 3.2 mm and 24.5%, respectively, in TRUS-Bx and 6.3 mm and 45.4% in MRI-visual-Bx (p<0.001). In addition,Gleason score ≥7 was noted more frequently using MRI-visual-Bx (p=0.028). The detection rate of clinically significant prostate cancer was 27/77 (35.1%) and 40/54 (74.1%) for TRUS-Bx and MRI-visual-Bx, respectively (p<0.001). Conclusion: MRI-visual-Bx showed better performance in the detection of clinically significant prostate cancer, compared to TRUS-Bx among patients with a PSA level less than 10 ng/mL.
Abstract
Purpose: To compare prostate cancer detection rates between 12 cores transrectal ultrasound-guided prostate biopsy (TRUS-Bx) and visually estimated multiparametric magnetic resonance imaging (mp-MRI)-targeted prostate biopsy (MRI-visual-Bx) for patientswith prostate specific antigen (PSA) level less than 10 ng/mL. Materials and Methods: In total, 76 patients with PSA levels below 10 ng/mL underwent 3.0 Tesla mp-MRI and TRUS-Bx prospectivelyin 2014. In patients with abnormal lesions on mp-MRI, we performed additional MRI-visual-Bx. We compared pathologic results,including the rate of clinically significant prostate cancer cores (cancer length greater than 5 mm and/or any Gleason grade greater than 3 in the biopsy core). Results: The mean PSA was 6.43 ng/mL. In total, 48 of 76 (63.2%) patients had abnormal lesions on mp-MRI, and 116 targeted biopsycores, an average of 2.42 per patient, were taken. The overall detection rates of prostate cancer using TRUS-Bx and MRI-visual-Bx were 26/76 (34.2%) and 23/48 (47.9%), respectively. In comparing the pathologic results of TRUS-Bx and MRI-visual-Bx cores, the positive rates were 8.4% (77 of 912 cores) and 46.6% (54 of 116 cores), respectively (p<0.001). Mean cancer core lengths and mean cancer core percentages were 3.2 mm and 24.5%, respectively, in TRUS-Bx and 6.3 mm and 45.4% in MRI-visual-Bx (p<0.001). In addition,Gleason score ≥7 was noted more frequently using MRI-visual-Bx (p=0.028). The detection rate of clinically significant prostate cancer was 27/77 (35.1%) and 40/54 (74.1%) for TRUS-Bx and MRI-visual-Bx, respectively (p<0.001). Conclusion: MRI-visual-Bx showed better performance in the detection of clinically significant prostate cancer, compared to TRUS-Bx among patients with a PSA level less than 10 ng/mL.
참고문헌 (33)
- Elabbady AA, "Extended 12-core prostate biopsy increases both the detection of prostate cancer and the accuracy of Gleason score", Eur Urol, 49, pp.49~53 (2006)
- Eichler K, "Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review", J Urol, 175, pp.1605~1612 (2006)
- Pepe P, "Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation", Urology, 70, pp.1131~1135 (2007)
- Heidenreich A, "Early detection of prostate cancer: European Association of Urology recommendation", Eur Urol, 64, pp.347~354 (2013)
- Ukimura O, "Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care", Eur Urol, 63, pp.214~230 (2013)
- Lawrentschuk N, "‘Prostatic evasive anterior tumours’: the role of magnetic resonance imaging", BJU Int, 105, pp.1231~1236 (2010)
- Dahabreh IJ, "Active surveillance in men with localized prostate cancer: a systematic review", Ann Intern Med, 156, pp.582~590 (2012)
- Lecornet E, "The accuracy of different biopsy strategies for the detection of clinically important prostate cancer: a computer simulation", J Urol, 188, pp.974~980 (2012)
- Taira AV, "Transperineal template-guided mapping biopsy as a staging procedure to select patients best suited for active surveillance", Am J Clin Oncol, 36, pp.116~120 (2013)
- Delongchamps NB, "Detection of significant prostate cancer with magnetic resonance targeted biopsies--should transrectal ultrasound-magnetic resonance imaging fusion guided biopsies alone be a standard of care?", J Urol, 193, pp.1198~1204 (2015)
- Belas O, "Prebiopsy multiparametric MRI of the prostate: the end of randomized biopsies?", Prog Urol, 22, pp.583~589 (2012)
- Delongchamps NB, "Prebiopsy magnetic resonance imaging and prostate cancer detection: comparison of random and targeted biopsies", J Urol, 189, pp.493~499 (2013)
- Haffner J, "Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection", BJU Int, 108(8 Pt 2), pp.E171~E178 (2011)
- Kuru TH, "Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer", J Urol, 190, pp.1380~1386 (2013)
- Siddiqui MM, "Magnetic resonance imaging", ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy, 2013, pp.64, 713~719
- Schoots IG, "Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis", Eur Urol, 68, pp.438~450 (2015)
- Valerio M, "Detection of clinically significant prostate cancer using magnetic resonance imaging-ultrasound fusion targeted biopsy: a systematic review", Eur Urol, 68, pp.8~19 (2015)
- Wysock JS, "A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial", Eur Urol, 66, pp.343~351 (2014)
- Puech P, "Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study", Radiology, 268, pp.461~469 (2013)
- Ploussard G, "The contemporary concept of significant versus insignificant prostate cancer", Eur Urol, 60, pp.291~303 (2011)
- Lee DH, "Comparison of pathological outcomes of active surveillance candidates who underwent radical prostatectomy using contemporary protocols at a high-volume Korean center", Jpn J Clin Oncol, 42, pp.1079~1085 (2012)
- Ong WL, "Transperineal biopsy prostate cancer detection in first biopsy and repeat biopsy after negative transrectal ultrasoundguided biopsy: the Victorian Transperineal Biopsy Collaboration experience", BJU Int, 116, pp.568~576 (2015)
- Onik G, "Three-dimensional prostate mapping biopsy has a potentially significant impact on prostate cancer management", J Clin Oncol, 27, pp.4321~4326 (2009)
- Grummet JP, "Sepsis and ‘superbugs’: should we favour the transperineal over the transrectal approach for prostate biopsy?", BJU Int, 114, pp.384~388 (2014)
- Radtke JP, "Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance", J Urol, 193, pp.87~94 (2015)
- Kasivisvanathan V, "Transperineal magnetic resonance image targeted prostate biopsy versus transperineal template prostate biopsy in the detection of clinically significant prostate cancer", J Urol, 189, pp.860~866 (2013)
- Moore CM, "Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group", Eur Urol, 64, pp.544~552 (2013)
- Hambrock T, "Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen", J Urol, 183, pp.520~527 (2010)
- Natarajan S, "Clinical application of a 3D ultrasound-guided prostate biopsy system", Urol Oncol, 29, pp.334~342 (2011)
- Fiard G, "Targeted MRI-guided prostate biopsies for the detection of prostate cancer: initial clinical experience with real-time 3-dimensional transrectal ultrasound guidance and magnetic resonance", transrectal ultrasound image fusion, 2013, pp.81, 1372~1378
- Mozer P, "First round of targeted biopsies using magnetic resonance imaging", ultrasonography fusion compared with conventional transrectal ultrasonography-guided biopsies for the diagnosis of localised prostate cancer, 2015, pp.115, 50~57
- Seo HK, "Detection rate of prostate cancer according to prostate-specific antigen and digital rectal examination in Korean men: a nationwide multicenter study", Urology, 70, pp.1109~1112 (2007)
- 안재현, "Nomogram for Prediction of Prostate Cancer with Serum Prostate Specific Antigen Less than 10 ng", mL, 2014, pp.29(3), 338~342[DOI]